四级新生儿重症监护病房实施万古霉素贝叶斯软件监测的考量
本文描述了在一个多院区学术医疗系统的四级新生儿重症监护病房(NICU)中,选择、规划和实施万古霉素模型引导精准给药(MIPD)贝叶斯软件的过程,约6个月完成。文章总结了新生儿实施MIPD时的特殊考量,包括药代动力学模型选择、协变量输入、血清肌酐检测方法、采血次数及体重选择等,供其他机构参考。
要点
- 新生儿万古霉素AUC监测可借助贝叶斯MIPD软件实施。
- 实施前需评估软件是否支持新生儿群体及电子病历整合。
- 新生儿实施需关注药代动力学模型选择与持续评估。
核心结论
- 本文分享了在新生儿群体中选择、规划和实施万古霉素AUC监测贝叶斯软件的经验,其他医疗系统和儿童医院可据此评估多种MIPD软件并在实施前考虑新生儿特殊问题。
研究设计与样本
- 本文为学术医疗系统内四级NICU多院区实施万古霉素MIPD贝叶斯软件的经验描述,实施过程约6个月完成。
主要发现
- 所选软件可捕获万古霉素以外药物数据、提供分析支持、包含新生儿等特殊群体并可将MIPD整合入电子健康记录。
- 儿科药学代表参与系统-wide项目团队,负责开发教育材料、起草政策程序变更并协助部门培训。
- 儿科和新生儿药师超级用户培训其他儿科药师,在上线周提供现场支持,并识别儿科和NICU特定实施细节。
关键数值与推荐
- 新生儿实施MIPD需考虑选择并持续评估适当的药代动力学模型。
- 需考虑随婴儿年龄增长选择适当模型、输入显著协变量、确定部位特异性血清肌酐检测方法。
- 需决定万古霉素血药浓度采血次数、辨别排除AUC监测的患者,并选择实际体重或剂量体重。
临床怎么用
- 其他医疗系统和儿童医院可参考本经验评估多种MIPD软件,并在实施前考虑新生儿特殊问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The updated 2020 vancomycin therapeutic drug monitoring guideline advocates for area under the curve (AUC)-based monitoring in neonates, preferably with Bayesian estimation. This article describes the selection, planning, and implementation of vancomycin model-informed precision dosing (MIPD) software with Bayesian estimation in the neonatal intensive care unit (NICU) within an academic health system. SUMMARY: The selection, planning, and implementation of vancomycin MIPD software was completed in approximately 6 months throughout a health system with multiple NICU sites. The chosen software captures data on medications in additional to vancomycin, provides analytics support, includes specialty populations (eg, neonates), and offers the ability to integrate MIPD into the electronic health record. Pediatric pharmacy representatives served on a system-wide project team with key responsibilities including development of educational materials, drafting changes to policies and procedures, and assistance with department-wide software training. Additionally, pediatric and neonatal pharmacist super users trained other pediatric pharmacists on software functionality, were available the week of go-live for in-person support, and contributed to the identification of pediatric and NICU-specific nuances related to software implementation. Neonatal-specific considerations when implementing MIPD software include: the selection of appropriate pharmacokinetic model(s), continued evaluation of such model(s), selection of appropriate model(s) in infants as they age, input of significant covariates, determination of the site-specific serum creatinine assay, decision of the number of vancomycin serum concentrations obtained, discernment of patients excluded from AUC monitoring, and the utilization of actual versus dosing weight. CONCLUSION: This article serves to share our experience with selecting, planning, and implementing Bayesian software for vancomycin AUC monitoring in a neonatal population. Other health systems and children's hospitals can utilize our experience to evaluate a variety of MIPD software and consider neonatal nuances prior to implementation.
引用
- Oliver MB, Boeser KD, Carlson MK, et al. Considerations for implementation of vancomycin Bayesian software monitoring in a level IV NICU population within a multisite health system. Am J Health Syst Pharm. 2023. PMID: 36860169. doi:10.1093/ajhp/zxad048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。